



Date: December 18, 2012

ELN Recommendation Meeting

Atlanta, United States, December 6, 2012

Organizer: Prof. Dr. Michele Baccharani

Summary

For the second update of the concepts and management recommendations of the European LeukemiaNet for the treatment of chronic myeloid leukemia (CML) a panel meeting was held on December 6, 2012 in Atlanta.

A publication of the new recommendations is planned for 2013.

Scientific content of and discussion at the workshops

Bcr-Abl tyrosine-kinase inhibitors (TKI) are the first-line therapy for most patients with chronic myeloid leukemia (CML). In more than 90% of the cases CML is caused by chromosomal abnormality due to fusion between Abelson (Abl) tyrosine kinase gene at chromosome 9 and break point cluster (Bcr) gene at chromosome 22, resulting in the chimeric oncogene Bcr-Abl and a constitutively active Bcr-Abl tyrosine kinase that has been implicated in the pathogenesis of CML. Compounds have been developed that selectively inhibit this tyrosine kinase. The first TKI called imatinib have changed fundamentally the outcome of the CML therapy. The optimal application and dosage of this new drug were tested in several clinical studies worldwide. Therefore recommendations were developed for the CML therapy (Baccharani et al. 2006). The recommendations include definitions of failure, suboptimal response, warnings, optimal response and recommendations for the treatment (http://www.leukemia-net.org/content/leukemias/cml/recommendations/index_eng.html). In 2009 the recommendations were updated regarding the upcoming second generation of TKI (Baccharani et al. 2009). The experience with the second generation TKI (e.g. Dasatinib, Nilotinib) in the last years and the development of third generation of TKI (e.g. Ponatinib, Bosutinib) require a second update of the recommendations. Also new results in research about early prediction and new risk scores have to be taken into consideration. For this purpose a panel of 31 members of the ELN Workpackage 4 (CML) was appointed. The first



panel meeting was held in San Diego (in the context of the ASH Annual Meeting, December 2011), followed by meetings in Amsterdam (EHA Annual Meeting, June 2012), in Baltimore (ESH Annual Meeting, September 2012) and now in Atlanta (ASH Annual meeting 2012). The meetings were confidential. In the last meeting the panel members reached a broad agreement so that a draft of the manuscript will be made and sent to the panel in January 2013. The publication of the recommendations is planned for 2013. Pocket cards to spread the recommendations will be prepared by the ELN network management center and provided on the ELN website after the recommendations have been published.

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.
Baccarani et al., Blood. 2006 Sep 15;108(6):1809-20.

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. Baccarani et al., J Clin Oncol. 2009 Dec 10;27(35):6041-51.

Assessment of results and impact of the workshops on the future direction of the field

The ELN recommendations are globally used for the management of CML. The recommendations guarantee an optimal treatment of CML patients wherever the drugs and medical standards are available.

Final Programme

4th EUROPEAN LEUKEMIANET PANEL MEETING FOR CHRONIC MYELOID LEUKEMIA

6.12.2012 8:30 – 12:30 Atlanta Marriott Suites Midtown, Atlanta

Update of the concepts and management recommendations of European LeukemiaNet
for the treatment of chronic myeloid leukemia